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Rac1 is a major player of the Rho family of small GTPases that controls multiple cell
signaling pathways, such as the organization of cytoskeleton (including adhesion and
motility), cell proliferation, apoptosis and activation of immune cells. In the nervous
system, in particular, Rac1 GTPase plays a key regulatory function of both actin and
microtubule cytoskeletal dynamics and thus it is central to axonal growth and stability,
as well as dendrite and spine structural plasticity. Rac1 is also a crucial regulator of
NADPH-dependent membrane oxidase (NOX), a prominent source of reactive oxygen
species (ROS), thus having a central role in the inflammatory response and neurotoxicity
mediated by microglia cells in the nervous system. As such, alterations in Rac1 activity
might well be involved in the processes that give rise to Amyotrophic Lateral Sclerosis
(ALS), a complex syndrome where cytoskeletal disturbances in motor neurons and redox
alterations in the inflammatory compartment play pivotal and synergic roles in the final
disease outcomes. Here we will discuss the genetic and mechanistic evidence indicating
the relevance of Rac1 dysregulation in the pathogenesis of ALS.
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INTRODUCTION
Degeneration of motor neurons in the brain cortex, brainstem
and spinal cord of patients is the most recognized feature of
Amyotrophic Lateral Sclerosis (ALS). Since the discovery of the
first gene associated to familial forms of ALS, Sod1, many fun-
damental achievements in clinical, genetic, and basic biology
processes related to ALS have profoundly improved our knowl-
edge of the disease (Cozzolino et al., 2012). Indeed, while it
has long been thinking that ALS was a disease highly specific
for motor neurons, with a low albeit significant incidence of
genetics limited to familial forms, it is now widely accepted
that ALS is a complex syndrome that involves a wide range of
different tissues and cell types, including muscle cells, astro-
cytes, microglia, oligodendrocytes. Further, it is clear that genes
have a profound impact on the overall disease pathogenesis,
even in apparently sporadic forms (Renton et al., 2014). To
make things more intricate, many of the recently identified
gene mutations that are definitely involved in familial (and to
some degrees in sporadic) forms of ALS are also responsi-
ble of, or associated to diseases that do not primarily mani-
fest as motor neuron diseases, ranging from Fronto Temporal
Dementia (FTD) to Huntington Disease Phenocopies, putting
in the spotlight the concept that ALS is part of a more
widespread and complex disease process (Cooper-Knock et al.,
2014).
Although different mechanisms have been invoked to play a
role in the pathogenesis of ALS (Cozzolino et al., 2012), RNA
metabolism has emerged as a fundamental aspect of disease
determination. Two different lines of reason support this con-
clusion. First, recent genetic evidence pinpointed at least three
different genes whose mutations, together accounting for nearly
50% of familial ALS cases, are likely responsible for disease-
relevant alterations in RNA control. These genes include TARDBP
(Neumann et al., 2006), FUS/TLS (Vance et al., 2009), and c9orf72
(DeJesus-Hernandez et al., 2011; Renton et al., 2011). In all cases,
mutations in these genes are believed to alter the control of
RNA processing, including mRNA transcription, splicing, trans-
lation and transport (Ling et al., 2013), although the particular
step of RNA metabolism that is affected in ALS is still to be
ascertained.
Second, analogies with another Motor Neuron Disease
(MND), namely Spinal Muscular Atrophy (SMA), sustain the
idea that post-transcriptional gene regulation is profoundly
affected in MND, including ALS. Indeed, SMA is caused by
a decreased availability of the Survival Motor Neuron protein
(SMN), due to gene mutations or deletions in the smn1 gene,
and this leads to an early degeneration of lower motor neurons
in children. SMN is known to play a crucial function both
in the biogenesis and localization of small ribonucleoprotein
particles (snRNPs), the core modules of the splicing machinery
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(Burghes and Beattie, 2009), and in the transport along neu-
ronal processes of cytosolic mRNAs-containing granules (Rage
et al., 2013), an essential process that guarantees local protein
synthesis (Jung et al., 2014). This is particularly important in,
although not limited to, neurons, where local mRNA translation
sustains axon elongation and maintenance, as well as synapses
formation and plasticity (Jung et al., 2012). Thus, in the com-
plete absence of SMN, cells and animals die (Schrank et al.,
1997), to testify the widespread and essential role of SMN,
while the shortage of SMN protein is particularly harmful to
neurons. Although the reasons why a decreased availability of
SMN activates a very selective process that leads to the specific
degeneration of lower motor neurons is far from being clear,
evidence exist that mys-functioning in SMN-regulated processes
might be shared by ALS (Yamazaki et al., 2012; Gerbino et al.,
2013; Groen et al., 2013; Turner et al., 2014), further indicating
that motor neurons are particularly vulnerable to disturbed RNA
metabolism.
EVIDENCE POINTING TO DYS-REGULATION OF ACTIN
DYNAMICS IN MNDs: RHO GTPases AND MOTOR NEURONS
The overlap between ALS and SMA is not however restricted
to RNA control. Indeed, ALS and SMA share actin dynamics
disturbances as a central route for motor neuron degeneration.
In particular, the regulation of actin dynamics at the synapse,
which is accomplished by a plethora of actin-binding/-regulating
proteins is crucial for the proper function and maturation of
neuromuscular junctions (NMJs), that are supposed to be a
primary, early target of both ALS and SMA (Fischer et al., 2004;
Kariya et al., 2008).
Both β-actin mRNA and protein are significantly reduced in
distal axons and growth cones of SMA motor neurons, thus estab-
lishing a link between actin perturbations to the degeneration
of NMJs in SMA (Rossoll et al., 2003). Similarly, overexpression
of SMN in cultured neuronal cells promotes neurite outgrowth,
while downregulation has an opposite effect (van Bergeijk et al.,
2007). This is the consequence of changes in the ratio between
F- and G-actin, further indicating that SMN regulates actin
dynamics. Actually, the overexpression in SMA motor neurons
of the actin-binding protein plastin 3, a genetic modifier for
SMA (Oprea et al., 2008), rescues defects due to decreased SMN
(Ackermann et al., 2013). Microfilament dynamics are also appar-
ently mediated by profilins (Birbach, 2008) and SMN was shown,
in particular, to bind and regulate the expression of profilin2a,
which is known to promote actin polymerization (Nölle et al.,
2011). Profilin2a is a key player in the Rho-kinase (ROCK) path-
way, and loss of SMN results in an increased activity of the small
GTPase RhoA, and an increased binding of profilin2a to ROCK, a
direct downstream effector of RhoA. RhoA-mediated activation
of ROCK then leads to a consequent ROCK-dependent hyper-
phosphorylation of profilin2a which in this form eventually
represses neurite outgrowth in neuronal cells (Bowerman et al.,
2010; Nölle et al., 2011). The functional relevance of this pathway
is clearly demonstrated by the observation that treating SMA
mice with ROCK inhibitors strongly improves the maturation of
the NMJs, increases muscle fiber size and prolongs their survival
(Bowerman et al., 2010, 2012).
Motor neuron loss is also delayed in experimental models
of ALS by fasudil, a clinical approved ROCK inhibitor (Takata
et al., 2013). These results thus indicate that a similar pattern of
deregulation affecting the RhoA/ROCK/profilin pathway might
be operating in the degenerating motor neurons in ALS. Muta-
tions within the profilin 1 (PFN1) gene have been identified in
late 2012 to cause ALS in two large families (Wu et al., 2012).
PFN1 is crucial for the conversion of monomeric to filamentous
actin, and ALS-linked PFN1 mutations were shown to reduce
the ability of PFN1 to bind actin and to induce a decrease in
the ratio of F/G actin. This eventually leads to inhibition of
neurite outgrowth and alteration in growth cone morphology,
all features clearly reminiscent of actin dynamics disturbances.
Although later mutational screening in worldwide ALS popula-
tions established that PFN1 gene mutations are a very rare cause
of familial ALS (van Blitterswijk et al., 2013), these findings,
together with the association of familial ALS to rare mutation
in cytoskeleton-regulating genes such as neurofilament heavy
polypeptide, peripherin and dynactin provide a considerable
genetic basis to disruption of actin cytoskeleton as a possible
pathogenic mechanism in motor neuron degeneration (Renton
et al., 2014).
As central regulators of actin dynamics, Rho family of small
GTPases, with RhoA, Rac1 and cdc42 the most studied mem-
bers, are natural candidates to play a role in these processes. A
growing body of evidence suggests, in particular, that inhibition
of Rac1 mediates the process of motor neuron degeneration
in ALS. Mutations in ALS2 were described to be responsible
for a recessive form of juvenile-onset ALS (Yang et al., 2001),
although later studies have suggested that ALS2-induced disease
phenotypes are more related to slowly progressive, juvenile forms
of hereditary spastic paraplegia (Panzeri et al., 2006). Nonetheless,
ALS2 encodes for the protein alsin, which has been character-
ized as a guanine nucleotide exchange factor (GEF) for Rho
family of small GTPases, including Rac1, and mutation in alsin
are expected to affect GEF activity of this protein (Yang et al.,
2001; Topp et al., 2004). In line with its activatory function,
alsin knockdown inhibits axon growth and induces cell death
in cultured motor neurons, further indicating the importance
of cytoskeletal balance in motor neuron health. Importantly, cell
death and cytoskeletal alterations are obtained in the same cells
by overexpression of a dominant-negative Rac1 mutant, while a
constitutively active Rac1 mutant is able to inhibit it (Jacquier
et al., 2006). Moreover, the apoptotic phenotypes induced in
NSC34 motor neuron-like cells by overexpression of mutSOD1
are inhibited by co-expression of alsin, and this neuroprotective
activity is completely abolished by decreasing endogenous Rac1
with siRNA (Kanekura et al., 2005), indicating that Rac1 acts
downstream of alsin. Overall, these observations clearly indi-
cate that disruption of Rac1 GTPase function is a contributing
event in motor neuron degeneration in ALS. This conclusion
is further supported by findings from experiments in cultured
neuronal cells depleted of TDP43. Indeed, TDP43 knockdown
in neuronal cells inhibits neurite outgrowth and induces cell
death, as a consequence of decreased membrane association and
inactivation of RhoA, Rac1, and cdc42 Rho GTPases (Iguchi et al.,
2009). However, it has also been shown that TDP43 knockdown
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in hippocampal neurons is able to repress Rac1 expression at
a translational level, and this causes a significant increase in
the density of dendritic spines (Majumder et al., 2012), thus
further indicating that the outcome of Rho GTPases activity is
indeed a unique feature depending on the specific neuronal cell
subpopulation.
All these results point to Rac1-dependent cytoskeletal dys-
regulation as a key determinant of motor neuron degeneration.
However, beyond their characterized function in actin dynamics,
Rho GTPase signaling is also involved in other important cellular
processes (Linseman and Loucks, 2008) that might be altered
in ALS. An important link between Rac1 and motoneuronal
cell viability was provided by the observation that the over-
expression of mutSOD1 proteins decreases the levels of active,
GTP-bound form of Rac1 and induces apoptosis in SH-SY5Y
neuronal cell lines (Pesaresi et al., 2011). Importantly, the over-
expression of a constitutive active form of Rac1 (V12) fully
protects SH-SY5Y cells from apoptosis, whereas a dominant-
negative, inactive form of mutant of Rac1 (N17) is per se suf-
ficient to induce apoptotic cell death. Thus, Rac1 inhibition
is anticipated to have a critical role in motor neurons demise
in ALS. Yet, a direct evidence that this is occurring in motor
neurons in vivo, has not been reported so far. Interestingly,
the inhibition of Rac1 by mutSOD1s is strictly dependent on
the activation of a signaling pathway which originates from
mitochondria and is mediated by the p66KDa isoform of the
adaptor protein Shc (p66Shc): when mitochondrial damage is
prevented by p66Shc functional inhibition, Rac1 activity is res-
cued, and cell survival recovered. Thus, damage to mitochondria,
which represent a well recognized, early sign of motor neuron
degeneration in ALS, might represent the trigger of a patholog-
ical cascade involving Rac1 dysregulation, eventually leading to
both actin cytoskeleton disturbances and loss of cell viability.
In addition, these data point to mitochondria-derived reactive
oxygen species (ROS) as mediators of Rac1 inhibition. Many
types of hints are indeed accumulating, which indicate that Rho
family GTPases are a redox sensitive family of proteins (Mitchell
et al., 2013). This is of crucial importance in ALS, a pathological
condition that is associated to critical alterations in the redox
balance which exert detrimental effects not only at the level of
NMJ (Pollari et al., 2014), but also in the inflammatory com-
partment where ROS-mediated microglial cells activation plays
a fundamental role in ALS disease progression (Boillée et al.,
2006).
Rac1 AS A MAJOR PLAYER IN INFLAMMATION IN ALS
The neuroinflammatory process is a feature common to all ALS
forms, either sporadic or familial, and in the latter case all ALS-
causative genes exert a comparable activation of the glial com-
partment, despite their specific function (Philips and Robberecht,
2011; Rizzo et al., 2014). It is commonly believed that the neu-
roinflammatory reaction played in particular by microglia, the
resident immune cells of the CNS, exerts a protective function at
early stages of the pathology that is switched into a detrimental
one as the disease progresses (Appel et al., 2011). Accordingly,
microglia cells producing trophic, beneficial effects are said to
belong to the M2 phenotype, whilst the toxic phenotype is defined
as M1. In response to stimuli derived from damaged motor neu-
rons and from autocrine/paracrine glial signaling, M1 microglia
produces and releases ROS and pro-inflammatory cytokines that
are responsible for a self-propagating cycle of progressive and irre-
versible motor neuron death (Henkel et al., 2009). The inhibition
of such damaging pro-inflammatory process is therefore a main
field in ALS research and one target of interest in this context is
NOX.
In particular, NOX2 (gp91phox) is a major source of super-
oxide by phagocytic cells (Bedard and Krause, 2007), and is the
predominant isoform found in microglia, astrocytes and neu-
rons (Sorce and Krause, 2009), where its activation results in a
neurotoxic outcome (Marchetto et al., 2008; Liao et al., 2012).
NOX2 expression is upregulated both in familial and sporadic
ALS patients and in different ALS-animal models, and NOX2
inhibition by genetic ablation in SOD1-G93A mice significantly
slows disease progression and extends survival (Wu et al., 2006;
Marden et al., 2007). Pharmacological inhibition of NOX2 by
apocynin was shown to protect motor neurons from mutant
SOD1 toxicity in culture (Harraz et al., 2008; Marchetto et al.,
2008; Trumbull et al., 2012), but gave contrasting results when
administered to SOD1-G93A mice (Harraz et al., 2008; Trumbull
et al., 2012). Anyway, NOX2 is considered one of the main
markers of M1-toxic microglia. NOX2 consists of the integral
membrane subunits gp91Phox and p22Phox, which are perma-
nently associated with each other to form the catalytic flavo-
cytochrome b558 core (cyt b558), the cytosolic subunits p40Phox,
p47Phox, p67Phox and Rac1. Upon activation, the cytosolic factors
translocate to membranes to interact with cytb558, through which
electrons from NADPH are transported to reduce molecular
oxygen to superoxide. Active, GTP-bound Rac1 acts both as an
adaptor, to ensure correct positioning of p67Phox toward cytb558,
and as a player in the electron-transfer reaction (Bedard and
Krause, 2007).
In ALS, uncontrolled Rac1 activation represents a straight link
between disease-causing mutSOD1s and NOX2-mediated ROS
production by glial cells. It was in fact clearly demonstrated
that SOD1 directly binds to Rac1 in a redox-sensitive man-
ner, influencing the rate of intrinsic GTP hydrolysis, and thus
of Rac1 activity: in reducing conditions SOD1 binds to Rac1
and stimulates its activity; conversely, in oxidizing conditions
SOD1 dissociates from Rac1, favoring GTP to GDP exchange
and thus eventually silencing Rac1-dependent activity of NOX2.
This mechanism is found dysregulated in glial cells by different
SOD1 mutants, that are less sensitive to redox uncoupling, in
particular in a subpopulation of early endosomes containing
NOX2, called redoxosomes (Harraz et al., 2008; Li et al., 2011).
As a matter of fact, expression of mutSOD1s in glial cells elevates
the levels of GTP-bound Rac1 (Harraz et al., 2008), that are also
found dramatically increased in microglia derived from SOD1-
G93A mice (Apolloni et al., 2013). ROS generated by the Rac1-
NOX2 axis are then responsible for TNFα secretion, autocrine
and paracrine induction of the pro-inflammatory transcription
factor NFκB in co-cultured neurons and neurotoxicity (Li et al.,
2011). Substantial raise of active Rac1 is also found in spinal
cord from SOD1-G93A mice, with consequent hyperactivation of
NOX2 (Harraz et al., 2008).
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The overactivation of Rac1/NOX2 pathway in vivo could be
also the resultant of the action of different pro-inflammatory
molecules, such as extracellular ATP. This nucleotide is an acti-
vator of microglia response through purinergic receptors and it
is supposed to be increasingly released during neuronal damage.
In ALS, the P2X7 receptor preferential agonist 2′-3′-O-(benzoyl-
benzoyl) ATP, enhances the neurotoxic potential of SOD1-G93A
microglia and increases the production of ROS through the
recruitment of Rac1 and NOX2. Conversely, different P2X7 antag-
onists restore ROS production to basal levels decreasing the
amount of Rac1-GTP and inhibiting NOX2 activity (Apolloni
et al., 2013).
A role for Rac1 in ALS neuroinflammation is also suggested
by the interplay between alsin and SOD1-G93A in influencing
the dynamics of ROS production in glial cells. Alsin is known
to bind three components of the redoxosome: it possesses Rho-
GEF domains for Rac1 and Rab5 and it also interacts with
SOD1. When coexpressed with SOD1-G93A, alsin was shown to
attenuate SOD1-dependent Rac1 activation, ROS generation by
NOX2, NFκB induction, TNFα secretion and to protect neurons
from toxicity in co-culture studies (Li et al., 2011). This protec-
tive effect is in line with the detrimental one exerted by alsin
knockdown in motor neurons (Jacquier et al., 2006) and appears
to be mediated by the ability of alsin to decrease Rac1 activa-
tion in the presence of SOD1-G93A. These findings suggest that
independent ALS disease-associated genes may converge on the
same pathogenic pathway, i.e., the Rac1/NOX2 ROS-generating
mechanism.
THERAPEUTIC PERSPECTIVES TARGETING Rac1
In this review, we have shown how cytoskeletal dynamics alter-
ations in motor neurons as well as neuroinflammatory events in
microglia underlie the pathogenesis of ALS and other MNDs, and
how Rac1 GTPase might be involved in both processes. Although
many gaps exist in our knowledge about the mechanistic aspects
of these processes, Rac1 should be considered as a valuable target
to interfere with the disease development.
Like other Rho GTPases, Rac1 represents a hub that responds
to different signaling networks and in turn results in different,
even contrasting outcomes by interacting with many diverse
downstream effectors, that might well be different depending
on the cell type as well as the stimulus involved. Thus, the
apparently contradictory evidence about the activity of Rac1 in
ALS motor neurons and microglia should not be regarded as
surprising. Yet, the antagonistic effects that Rac1 targeting might
have on the motor neurons as opposed to the inflammatory
compartments poses some questions about how to devise an
effective strategy, that will need to be answered in the near
future. Nonetheless, a significant body of studies performed in
contexts where aberrant Rac1 signaling is associated to alterations
in neuronal structural plasticity and actin cytoskeleton dynam-
ics indicates that the modulation of Rac1-dependent signaling
pathways could be effective to protect neuronal degeneration
(Lorenzetto et al., 2013; Tönges et al., 2014; Travaglione et al.,
2014). Of course, an accurate preclinical evaluation in animal
models of ALS, that are widely available, will help answering these
questions.
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